{"id":35236,"date":"2024-04-23T13:07:21","date_gmt":"2024-04-23T11:07:21","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=35236"},"modified":"2024-04-23T12:12:21","modified_gmt":"2024-04-23T10:12:21","slug":"intrazerebrale-blutung-unter-oraler-antikoagulation-time-is-brain-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2024\/intrazerebrale-blutung-unter-oraler-antikoagulation-time-is-brain-cme","title":{"rendered":"Intrazerebrale Blutung unter oraler Antikoagulation: \u201eTime is brain\u201c [CME]"},"content":{"rendered":"<p>Eine intrazerebrale Blutung (ICB) ist wohl der gef\u00e4hrlichste zerebrale Insult: Jeder zweite Betroffene stirbt innerhalb von 3\u00a0Monaten, 60% innerhalb eines Jahres . H\u00e4ufigster Risikofaktor ist eine arterielle Hypertonie, besonders in Kombination mit einer oralen Antikoagulation (OAK). Die Deutsche Gesellschaft f\u00fcr Neurologie (DGN) empfiehlt in der S2k-Leitlinie zur \u201eBehandlung von spontanen intrazerebralen Blutungen\u201c (g\u00fcltig bis 30.6.2025) [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eine intrazerebrale Blutung (ICB) ist wohl der gef\u00e4hrlichste zerebrale Insult: Jeder zweite Betroffene stirbt innerhalb von 3\u00a0Monaten, 60% innerhalb eines Jahres . H\u00e4ufigster Risikofaktor ist eine arterielle Hypertonie, besonders in Kombination mit einer oralen Antikoagulation (OAK). Die Deutsche Gesellschaft f\u00fcr Neurologie (DGN) empfiehlt in der S2k-Leitlinie zur \u201eBehandlung von spontanen intrazerebralen Blutungen\u201c (g\u00fcltig bis 30.6.2025) [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[137,60,2305,1314,1312,2068,5998,1328,1327,138,5997,2304,56,136],"class_list":["post-35236","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikoagulanzien","tag-apoplektischer-insult","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-inch-studie","tag-neue-orale-antikoagulanzien","tag-noak","tag-phenprocoumon","tag-retrace-studie","tag-rivaroxaban","tag-schlaganfall","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/35236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=35236"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/35236\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=35236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=35236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=35236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}